2-[6-(Cyclopentylamino)-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-[6-(Cyclopentylamino)-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol
• 英文别名: 2-[6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C₁₅H₂₁N₅O₄
• 分子量: 335.36
• InChiKey: SQMWSBKSHWARHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• [EN] ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES<br/>[FR] THIAZOLOTRIAZOLES ET THIAZOLOIMIDAZOLES ARYLSUBSTITUÉS
  申请人：HENGRUI USA LTD

  公开号：WO2013049585A1

  公开（公告）日：2013-04-04

  This disclosure relates to compounds, compositions and methods for the treatment of various disorders. In particular, the disclosure relates to thiazolotriazole and thiazoloimidazole compounds which agonize the activity of the protein TGR5. Formula (I)

  这项披露涉及用于治疗各种疾病的化合物、组合物和方法。具体而言，该披露涉及嘧啶并咪唑和嘧啶并咪唑化合物，这些化合物激活蛋白质TGR5的活性。公式（I）
• Partial and full agonists of A1 adenosine receptors
  申请人：——

  公开号：US20030232783A1

  公开（公告）日：2003-12-18

  Disclosed are novel compounds that are partial and full A 1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.

  披露了一种新型化合物，它们是A1腺苷受体的部分和完全激动剂，适用于治疗各种疾病状态，特别是心动过速和心房扑动、心绞痛、心肌梗死和高脂血症。
• PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS
  申请人：Ibrahim Prabha

  公开号：US20090325896A1

  公开（公告）日：2009-12-31

  Disclosed are novel compounds that are partial and full A 1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.

  本发明涉及一种新型化合物，其为A1腺苷受体的部分和完全激动剂，可用于治疗各种疾病状态，特别是心动过速和心房颤动、心绞痛、心肌梗死和高脂血症。
• PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1476455A1

  公开（公告）日：2004-11-17
• COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND CARBONIC ANHYDRASE INHIBITORS FOR REDUCING INTRAOCULAR PRESSURE
  申请人：Inotek Pharmaceuticals Corporation

  公开号：EP2555775A1

  公开（公告）日：2013-02-13